ADPT
Adaptive Biotechnologies CorpNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$2.22B
P/E Ratio
—
EPS
$-0.32
Beta
2.16
52W High
$20.76
52W Low
$8.96
50-Day MA
$13.82
200-Day MA
$15.13
Dividend Yield
—
Profit Margin
-16.80%
Forward P/E
—
PEG Ratio
0.00
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Fundamentals
| Revenue (TTM) | $295.41M |
| Gross Profit (TTM) | $129.13M |
| EBITDA | $-29.79M |
| Operating Margin | -27.10% |
| Return on Equity | -24.00% |
| Return on Assets | -5.74% |
| Revenue/Share (TTM) | $1.93 |
| Book Value | $1.35 |
| Price-to-Book | 10.27 |
| Price-to-Sales (TTM) | 7.52 |
| EV/Revenue | 7.04 |
| EV/EBITDA | -1.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 35.10% |
| Shares Outstanding | $160.04M |
| Float | $125.30M |
| % Insiders | 1.84% |
| % Institutions | 96.48% |
Historical Volatility
HV 10-Day
49.08%
HV 20-Day
52.88%
HV 30-Day
55.38%
HV 60-Day
68.85%
HV Rank
32.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($20.14 target)
2
Strong Buy5
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026